Quest Diagnostics (DGX)
(Delayed Data from NYSE)
$153.95 USD
-1.30 (-0.84%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $153.88 -0.07 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$153.95 USD
-1.30 (-0.84%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $153.88 -0.07 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth F Momentum B VGM
Zacks News
AtriCure (ATRC) Gains China Approval for AtriClip LAA System
by Zacks Equity Research
AtriCure (ATRC) receives NMPA approval to market AtriClip Left Atrial Appendage Exclusion System in China, marking a significant step in global expansion.
Quest Diagnostics' (DGX) Haystack Oncology Forges New MRD Deal
by Zacks Equity Research
Quest Diagnostics' (DGX) subsidiary, Haystack Oncology, partners on the use of its MRD technology.
Cardinal Health's (CAH) China Syringe Makers Face FDA Warnings
by Zacks Equity Research
FDA investigations into Cardinal Health's (CAH) China-based syringe manufacturers, Jiangsu Shenli and Jiangsu Caina, reveal significant quality violations, prompting recalls and import alerts.
Quest Diagnostics (DGX) Tops Q2 Earnings, Raises 2024 Outlook
by Zacks Equity Research
Quest Diagnostics (DGX) delivers impressive base business growth in the second quarter of 2024.
Quest Diagnostics (DGX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 1.73% and 0.50%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Patterson (PDCO) Expands AI Solutions in Canada via Alliance
by Zacks Equity Research
Patterson Companies (PDCO) unit and Pearl collaborate to bring advanced AI disease detection technology, Second Opinion, to Canada's dental practices, enhancing clinical performance and patient communication
Edwards Lifesciences (EW) Buys Innovalve to Boost TMVR Solutions
by Zacks Equity Research
Edwards Lifesciences (EW) exercises the option to acquire Innovalve Bio-Medical Ltd., strengthening its TMVR technology portfolio and addressing unmet needs in structural heart disease.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AMN Healthcare (AMN) Unveils ShiftWise Flex Manager Hub App
by Zacks Equity Research
AMN Healthcare's (AMN) Manager Hub app, part of the ShiftWise Flex platform, revolutionizes workforce management for healthcare organizations with enhanced mobile capabilities and comprehensive insights.
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BD (BDX) Up on Efforts to Tackle Blood Culture Vial Shortage
by Zacks Equity Research
BD (BDX) faces a shortage of blood culture vials due to supplier issues. It is ramping up production and collaborating with the FDA to ensure patient care remains unaffected.
Quest Diagnostics Incorporated (DGX) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Quest Diagnostics (DGX) Set to Acquire OhioHealth's Lab Services
by Zacks Equity Research
Quest Diagnostics' (DGX) new agreement is likely to help expand access to cost-effective and advanced laboratory services in Ohio.
What Awaits Quest Diagnostics (DGX) in Q2 Earnings Release?
by Zacks Equity Research
Quest Diagnostics (DGX) is likely to have maintained its robust base business performance in the second quarter of 2024. However, nosediving COVID-19 testing revenues may limit growth.
Quest Diagnostics (DGX) to Expand in Canada With LifeLabs Buyout
by Zacks Equity Research
By integrating LifeLabs into its operations, Quest Diagnostics (DGX) aims to enhance the accessibility and quality of diagnostic services for Canadians.
Quest Diagnostics (DGX) Inks Deal to Acquire Allina Health
by Zacks Equity Research
Quest Diagnostics (DGX) signs an agreement to acquire Allina Health's select laboratory assets. The deal is aimed at expanding Quest Diagnostics' laboratory services across Minnesota and western Wisconsin.
Is It Apt to Hold Quest Diagnostics (DGX) Stock for Now?
by Zacks Equity Research
Strength in the core business bodes well for Quest Diagnostics (DGX). However, mounting debt levels and reduced COVID-19 testing revenues pose concerns.
Quest Diagnostics (DGX) Gains From New M&As Amid Competition
by Zacks Equity Research
In Physician Lab Services, Quest Diagnostics (DGX) is benefiting from the broad-based return to care, overall market growth and share gains driven by the competitive strength of its scale and innovative offerings.
Quest Diagnostics' (DGX) New Buyout Ramps Up Cancer Diagnosis
by Zacks Equity Research
Quest Diagnostics (DGX) completes the acquisition of PathAI Diagnostics, accelerating the adoption of AI and digital pathology to improve cancer diagnosis.
Take the Zacks Approach to Beat the Markets: Snap, Naspers, e.l.f. Beauty in Focus
by Santanu Roy
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Take the Zacks Approach to Beat the Markets: Robinhood Markets, Victory Capital, NVIDIA in Focus
by Santanu Roy
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Why Is Amedisys (AMED) Up 5.5% Since Last Earnings Report?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Quest Diagnostics (DGX) Up 3.1% Since Last Earnings Report?
by Zacks Equity Research
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Take the Zacks Approach to Beat the Markets: Goldman Sachs, Rush Street Interactive, Atmus Filtration Technologies in Focus
by Santanu Roy
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Quest Diagnostics (DGX) Grows in Digital Pathology With New Deal
by Zacks Equity Research
Quest Diagnostics' (DGX) pathology laboratories nationwide are set to get a boost with PathAI's AISight digital pathology image management system.